Pancragen has the most developed record of the three peptides in this set: rat diabetes models, two small studies in old rhesus monkeys, cell-culture work, and one small human study in older adults with type 2 diabetes.
Pancragen Prices
5 vendors · 0 with an issuer-verified COA · lowest 10mg from $38.88 · checked
Where to buy Pancragen: 5 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $38.88 | Buy Pancragen from Pantheon Peptides | |
| $51.99 | Buy Pancragen from Cenexa Labs | |
| $55.24 | Buy Pancragen from SomaChems | |
| $61.4610mg packageChecked today | Buy Pancragen from Regenix Peptides | |
| $85.47 | Buy Pancragen from BioLongevity Labs |
Tracked every day
Pancragen listing prices, tracked daily
The five cheapest in-stock package prices for Pancragen on each collected day, and the vendors that most often held those places.
No collected listings for this compound yet.
Current market data
Pancragen Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Pancragen is $38.88 from Pantheon Peptides. The median across vendors is $55.24.
- Lowest 10mg cost
- $38.88Pantheon Peptides
- Median 10mg cost
- $55.24One normalized offer per vendor
- Lowest package total
- $38.88Pantheon Peptides · package size may differ
- Public COA coverage
- 100%5 of 5 vendors
What the market shows
PeptidePrices found 5 in-stock listings from 5 vendors, checked through Oct 8, 2026. The lowest 10mg cost is 30% below the vendor median of $55.24; 2 vendors (40%) fall below that median. 5 of 5 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Pancragen? Research, safety, and status
Pancragen is a four-amino-acid peptide: lysine, glutamic acid, aspartic acid, tryptophan, with an amide cap on the C-terminus. Khavinson's 2005 paper explains the design. Comparing the sequences of insulinotropic (insulin-releasing) polypeptides, the group found a shared four-residue fragment, then synthesized "KEDWa," a version protected from gastrointestinal proteases. The "a" is the amide.
The proposed mechanism follows the group's general model. The peptide is said to reach the nucleus and bind DNA. The 2005 paper suggested it switches on the preproinsulin gene by pairing with GGCAGG/CCTGCC sequences. A 2014 molecular-mechanics paper proposed GGCAG as the binding site, with contacts in both the major and minor grooves of DNA. A 2015 paper reported that KEDW changed DNA methylation at a few CpG sites in the FOXA2 promoter of cultured pancreatic cells, but the authors found no correlation with that gene's expression. All of this is modeling or cell culture from the developer group.
Key research takeaways
It was not found in the pancreas. Khavinson's 2005 paper says it was designed from a four-residue fragment shared by insulin-releasing polypeptides and made resistant to gut enzymes. A 2010 paper from the same group calls it an "endogenous" tetrapeptide. Those two descriptions do not agree.
The human study (Korkushko et al., 2011) randomized 33 patients already taking glibenclamide. The text says the 16 patients given Pancragen improved, but the published tables show the significant changes in the other group. We could not resolve that inconsistency from the paper.
Every study we found has Khavinson as an author or names his institute as the source of the peptide. No independent lab has replicated the glucose effects.
The developer literature describes the C-terminal amide. One online peptide database lists 576 Da, which fits the free acid instead. On a COA, that one-dalton difference matters.
Pancragen at a glance
PeptidePrices safety rating
6/10 · Not FDA-approved
Mechanism
Proposed pancreatic bioregulator; cell and animal studies report effects on pancreatic differentiation factors and glucose handling.
Research areas
Pancreas and glucose-metabolism bioregulator research. Human clinical benefit is not established.
Regulatory / research status
Research / preclinical only
Half-life
Not established in direct human pharmacokinetic studies.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Human safety data is sparse. The available evidence is mainly preclinical and small Russian studies from one research group, and it does not establish clinical efficacy.
Russian bioregulator; short peptide; limited but clean data. Human evidence is thin and mostly from one research group. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Pancragen has the most developed record of the three peptides in this set: rat diabetes models, two small studies in old rhesus monkeys, cell-culture work, and one small human study in older adults with type 2 diabetes.
- It was not found in the pancreas. Khavinson's 2005 paper says it was designed from a four-residue fragment shared by insulin-releasing polypeptides and made resistant to gut enzymes. A 2010 paper from the same group calls it an "endogenous" tetrapeptide. Those two descriptions do not agree.
- The human study (Korkushko et al., 2011) randomized 33 patients already taking glibenclamide. The text says the 16 patients given Pancragen improved, but the published tables show the significant changes in the other group. We could not resolve that inconsistency from the paper.
- Every study we found has Khavinson as an author or names his institute as the source of the peptide. No independent lab has replicated the glucose effects.
Selected references
- Effect of tetrapeptide on insulin biosynthesis in rats with alloxan-induced diabetes · PubMed, 2005
- Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus · PubMed, 2007
- Effects of pancragen on the differentiation of pancreatic cells during their ageing · PubMed, 2013
- Transport of biologically active ultrashort peptides using POT and LAT carriers · PubMed, 2022
- RLS Encyclopedia (rlsnet.ru) · rlsnet.ru
- Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide · PubMed, 2010
Related pages